Monday

2nd Oct 2023

Vaccine selfishness goes against science, EU regulator warns

  • Guido Rasi, the EMA director, was professor of microbiology at the University of Rome (Photo: eu2018.at)

People most in need, not national hoarders, should get the first shots of any future coronavirus vaccine, the EU medicines regulator has said.

The first batches should go to "people most at risk of infection", such as medical staff on the front lines or transport sector workers, not just in all EU countries, but internationally, Guido Rasi, who heads the European Medicines Agency (EMA) in Amsterdam, said on Monday (18 May).

Read and decide

Join EUobserver today

Become an expert on Europe

Get instant access to all articles — and 20 years of archives. 14-day free trial.

... or subscribe as a group

That would create a "first ring of protection", which could later be fanned out to other groups as vaccine stocks grew, he said.

Scientists would have to model details of which "communities" to immunise first, but the ring method was "the rational approach", Rasi added.

The EMA authorises medicines for EU-wide distribution.

Rasi, who used to be professor of microbiology at the University of Rome, spoke to MEPs on the European Parliament's health committee in a videoconference.

But despite the EMA's good services, vaccine production and distribution will be decided at national and corporate level in Europe and beyond.

There is no coronavirus vaccine yet.

But "we [countries] shouldn't fight each other. We should make it [a vaccine] available community-wise, not country-wise ... I feel strongly about this," Rasi said.

The European Commission and EMA were working on "joint procurement" of vaccines, he noted.

The EMA was also working on "compassionate use" authorisation, a special fast-track procedure, of Remdesivir.

The drug, developed by Irish company Gilead Sciences Ireland, has helped patients suffering from the Sars and Ebola viruses in the past.

The emergency EMA approval could be given "in the coming days", Rasi said.

Research on monoclonal antibodies was promising, he added, but he "didn't see anything" other than Remdesivir on the approval horizon.

Monoclonal antibodies are human proteins used by the immune system, which can be engineered by bio-tech firms to attack specific targets, such as coronavirus.

A coronavirus vaccine could be a goldmine for companies such as British and French pharmaceutical giants GlaxoSmithKline and Sanofi, who recently joined forces to create one.

And the EMA was being bombarded with new pitches by drugs firms, the agency's director noted.

It was a good idea to develop multiple vaccines at the same time, in order to increase availability and treatment options, Rasi said.

Some vaccines worked better in some demographics than others, the EU expert noted, and science never created panaceas that immunised 100 percent of patients with zero adverse reactions, he said.

EMA staff were "passionate" about stopping the pandemic, Rasi said.

The EMA had paused some publications because of the disruption caused by moving from London to the Netherlands after Brexit, he noted.

But it would be publishing all its research on corona-vaccines, he promised.

Vaccine sceptics

The good news was, the longer the virus stayed, the better the vaccines would become, Rasi said.

The bad news was it might not go away, like hepatitis or HIV, he added.

More bad news was that vaccine scepticism, popular fears about vaccine side-effects and conspiracy theories, could have a "very important negative effect" on the fight to stop coronavirus, Rasi said.

People should still take normal flu vaccines, not least so that doctors knew whether patients had flu or coronavirus, he said.

And as governments and industries pondered the long-term effect of events, Rasi, the EMA head, advised EU capitals to further integrate health policy.

Vaccine-production should also be brought closer to home, he added, in terms of Europe's medical security.

"Making vaccines in a third country gives us some vulnerability. Some 10 years ago we enjoyed a local capacity in Europe, but now it has been almost dismantled," he said.

"That's an overall pharmaceutical policy that Europe will have to consider," Rasi said.

Agenda

EU vaccine fundraising kicks off This WEEK

Worldwide efforts will be made to find €7.5bn for a possible cure for Covid-19. The commission will also flesh out its estimates of the coming recession.

EU launches funding drive for Covid-19 vaccine

The European Commission launches on Monday an initiative to raise €7.5bn to speed up the development of vaccines, treatment and testing capacity, ensuring that is equally "available to everyone and at affordable prices" and avoiding nationalisms.

EU wants to pay in advance for promising vaccines

EU health ministers will discuss on Friday plans to have the Commission negotiate with pharmaceutical companies on behalf of EU countries, make advaced payments and secure enough vaccines for Europeans.

Commission plans strategy to 'maximise' vaccine access

The EU Commission plans a vaccine stategy to make sure all citizens have access to it once it is ready, while it is also seeking to negotiate with pharmaceutical companies on securing the vaccine.

Opinion

Time for a reset: EU regional funding needs overhauling

Vasco Alves Cordeiro, president of the European Committee of the Regions, is advocating a revamp of the EU's regional policy so that it better supports all regions in addressing major challenges such as the green and digital transitions.

Opinion

How do you make embarrassing EU documents 'disappear'?

The EU Commission's new magic formula for avoiding scrutiny is simple. You declare the documents in question to be "short-lived correspondence for a preliminary exchange of views" and thus exempt them from being logged in the official inventory.

Latest News

  1. Hoekstra faces tough questioning to be EU Green chief
  2. Frontex shared personal data of NGO staff with Europol six times
  3. Why EU Commission dumped Google's favourite consultant
  4. Slovak's 'illiberal' Fico victory boosts Orban, but faces checks
  5. European Political Community and key media vote This WEEK
  6. Is the ECB sabotaging Europe's Green Deal?
  7. The realists vs idealists Brussels battle on Ukraine's EU accession
  8. EU women promised new dawn under anti-violence pact

Stakeholders' Highlights

  1. Nordic Council of MinistersThe Nordic Region is stepping up its efforts to reduce food waste
  2. International Medical Devices Regulators Forum (IMDRF)Join regulators, industry & healthcare experts at the 24th IMDRF session, September 25-26, Berlin. Register by 20 Sept to join in person or online.
  3. UNOPSUNOPS begins works under EU-funded project to repair schools in Ukraine
  4. Georgia Ministry of Foreign AffairsGeorgia effectively prevents sanctions evasion against Russia – confirm EU, UK, USA
  5. International Medical Devices Regulators Forum (IMDRF)Join regulators & industry experts at the 24th IMDRF session- Berlin September 25-26. Register early for discounted hotel rates
  6. Nordic Council of MinistersGlobal interest in the new Nordic Nutrition Recommendations – here are the speakers for the launch

Stakeholders' Highlights

  1. Nordic Council of Ministers20 June: Launch of the new Nordic Nutrition Recommendations
  2. International Sustainable Finance CentreJoin CEE Sustainable Finance Summit, 15 – 19 May 2023, high-level event for finance & business
  3. ICLEISeven actionable measures to make food procurement in Europe more sustainable
  4. World BankWorld Bank Report Highlights Role of Human Development for a Successful Green Transition in Europe
  5. Nordic Council of MinistersNordic summit to step up the fight against food loss and waste
  6. Nordic Council of MinistersThink-tank: Strengthen co-operation around tech giants’ influence in the Nordics

Join EUobserver

Support quality EU news

Join us